MDCC Molecular Devices (MM)

Molecular Devices Begins Shipping SynchroMax(TM) ET Plate Handling Robot SUNNYVALE, Calif., July 15 /PRNewswire-FirstCall/ -- Molecular Devices Corporation (NASDAQ:MDCC) today announced the first shipment of the SynchroMax ET Plate Handling Robot -- the latest addition to its line of microplate readers and liquid handling systems. The SynchroMax ET Plate Handler provides walk-away automation for ELISA workstations and cell-based screening units which include a Molecular Devices' SpectraMax(R) or Gemini microplate reader, AquaMax(R) dispenser or Embla washer. ELISA and cell-based screening assays make up the largest application segments for life sciences research. With the SynchroMax ET, researchers can run up to 320 microplates uninterrupted in 96-, 384- or 1536-well formats, improving efficiency and freeing up valuable research time. A complete, automated workstation can be purchased directly from Molecular Devices, eliminating the need to combine instrumentation from multiple vendors. The configuration and installation of the assay workstation by qualified Molecular Devices onsite application scientists provides optimal data quality and throughput. Molecular Devices' SpectraMax multimode detectors are a standard in academic, biotech and pharmaceutical industry laboratories for life sciences research. Together with SpectraTest(TM) instrument validation tools and SoftMax(R) Pro software data analysis and compliance capabilities, migrating automated assay workstations to the GLP/cGMP and FDA 21 CFR Part 11 environment can be achieved quickly. Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company's systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and combinatorial chemistry by facilitating the high-throughput and cost-effective identification and evaluation of drug candidates. The Company's solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. This press release contains "forward-looking" statements, including statements related to the prospects for or potential customer use of the SynchroMax(TM) ET Plate Handling Robot. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2003, as amended, and its quarterly report on Form 10-Q for the quarter ended March 31, 2004. Molecular Devices Corporation does not undertake any obligation to update forward-looking statements. DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533 Web site: http://www.moleculardevices.com/

Copyright